immunai.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $295.22MM
Immuani develops solutions for oncology treatments and auto-immune disorders by utilizing AI and ML technology to assist in mapping and to provide insights into the reprogramming of the immune system.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
10/27/2021 | Series C-2 | $15MM | $xx.xx | $1.15B | Koch Disruptive Technologies, Talos VC, 8VC, Alexanria Venture Investments, Piedmont, ICON | |
Price per Share
$xx.xx
Shares Outstanding
172,800
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Koch Disruptive Technologies, Talos VC, 8VC, Alexanria Venture Investments, Piedmont, ICON
|
||||||
10/27/2021 | Series C-1 | $204.34MM | $xx.xx | $1.15B | Koch Disruptive Technologies, Talos VC, 8VC, Alexanria Venture Investments, Piedmont, ICON | |
Price per Share
$xx.xx
Shares Outstanding
1,094,753
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Koch Disruptive Technologies, Talos VC, 8VC, Alexanria Venture Investments, Piedmont, ICON
|
||||||
02/11/2021 | Series B-2 | $2.99MM | $xx.xx | $240.97MM | Schusterman Foundation, Duquesne Family, Catalio Capital Management, Dexcel Pharma, Viola Ventures, TLV Partners | |
Price per Share
$xx.xx
Shares Outstanding
73,326
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Schusterman Foundation, Duquesne Family, Catalio Capital Management, Dexcel Pharma, Viola Ventures, TLV Partners
|
||||||
02/11/2021 | Series B-1 | $55.66MM | $xx.xx | $240.97MM | Schusterman Foundation, Duquesne Family, Catalio Capital Management, Dexcel Pharma, Viola Ventures, TLV Partners | |
Price per Share
$xx.xx
Shares Outstanding
1,088,327
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Schusterman Foundation, Duquesne Family, Catalio Capital Management, Dexcel Pharma, Viola Ventures, TLV Partners
|
||||||
05/14/2020 | Series Seed-2 | $5.3MM | $xx.xx | $38.16MM | Viola Ventures, TLV Partners | |
Price per Share
$xx.xx
Shares Outstanding
672,817
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Viola Ventures, TLV Partners
|
||||||
05/14/2020 | Series Seed-1 | $214,992 | $xx.xx | $38.16MM | Viola Ventures, TLV Partners | |
Price per Share
$xx.xx
Shares Outstanding
36,390
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Viola Ventures, TLV Partners
|
||||||
05/14/2020 | Series A | $12.05MM | $xx.xx | $38.16MM | Viola Ventures, TLV Partners | |
Price per Share
$xx.xx
Shares Outstanding
956,259
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Viola Ventures, TLV Partners
|